Changeflow GovPing Pharma & Drug Safety US12599617B2 Methods of Treating Head and Neck ...
Routine Notice Added Final

US12599617B2 Methods of Treating Head and Neck Cancers with Hemp Extract Containing CBD

Favicon for changeflow.com USPTO Patent Grants - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO granted Patent US12599617B2 to Dove Innovation Pty Limited covering methods of treating head and neck cancers using compositions containing hemp-derived CBD. The patent, with 17 claims, specifically covers mucosal formulations of cannabis extract for cancer treatment. Inventors include Alexandra M. Capano, Pradeep Singh Tanwar, and Alex Nance.

What changed

The USPTO issued Patent US12599617B2 to Dove Innovation Pty Limited for a method of treating head and neck cancers using hemp extract containing CBD, administered as a mucosal formulation. The patent contains 17 claims and names Alexandra M. Capano, Pradeep Singh Tanwar, and Alex Nance as inventors.

For pharmaceutical and biotech companies developing CBD-based therapeutics, this patent establishes IP protection in the head and neck cancer treatment space. Companies should review their R&D pipelines for potential overlap with these claims and consider proactive licensing strategies or design-around approaches to avoid infringement exposure.

What to do next

  1. Review patent claims for potential infringement
  2. Monitor for related USPTO filings by competitors
  3. Consult IP counsel regarding licensing opportunities

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Methods of treating head and neck cancers with hemp extract

Grant US12599617B2 Kind: B2 Apr 14, 2026

Assignee

Dove Innovation Pty Limited

Inventors

Alexandra M. Capano, Pradeep Singh Tanwar, Alex Nance

Abstract

A method for treating a head or neck cancer comprising: administering to a patient an effective amount of a composition comprising a cannabis extract comprising cannabidiol (CBD), wherein the composition is preferably administered as a mucosal formulation.

CPC Classifications

A61P 35/00

Filing Date

2022-10-26

Application No.

18049966

Claims

17

View original document →

Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12599617B2

Who this affects

Applies to
Pharmaceutical companies Medical device makers Healthcare providers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent portfolio management Pharmaceutical research IP licensing
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!